标题/作者	年份
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management A Tefferi, T Barbui American journal of hematology 95 (12), 1599-1613	2020
Natural killer cells in myeloid malignancies: immune surveillance, NK cell dysfunction, and pharmacological opportunities to bolster the endogenous NK cells M Carlsten, M Järås Frontiers in immunology 10, 2357	2019
The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder R Roskoski Jr Pharmacological research 151, 104567	2020
Iron: The cancer connection SV Torti, FM Torti Molecular aspects of medicine 75, 100860	2020
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study S Soverini, L Bavaro, C De Benedittis, M Martelli, A Iurlo, N Orofino, ... Blood, The Journal of the American Society of Hematology 135 (8), 534-541	2020
Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS) S Cirmi, A El Abd, L Letinier, M Navarra, F Salvo Cancers 12 (4), 826	2020
Third-line therapy for chronic myeloid leukemia: current status and future directions J Cortes, F Lang Journal of Hematology & Oncology 14, 1-18	2021
Molekulare Onkologie: Entstehung, Progression, klinische Aspekte; 95 Tabellen C Wagener, O Müller Georg Thieme Verlag	2010
Melittin—a natural peptide from bee venom which induces apoptosis in human leukaemia cells M Ceremuga, M Stela, E Janik, L Gorniak, E Synowiec, T Sliwinski, ... Biomolecules 10 (2), 247	2020
Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia—from molecular mechanisms to clinical relevance R Alves, AC Gonçalves, S Rutella, AM Almeida, J De Las Rivas, ... Cancers 13 (19), 4820	2021
Circ_0009910 promotes imatinib resistance through ULK1-induced autophagy by sponging miR-34a-5p in chronic myeloid leukemia H Cao, C Miao, L Sang, Y Huang, R Zhang, L Sun, Z Jiang Life sciences 243, 117255	2020
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study A Hochhaus, C Gambacorti-Passerini, C Abboud, BT Gjertsen, ... Leukemia 34 (8), 2125-2137	2020
UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma R Xu, Q Lin, X Qiu, J Chen, Y Shao, G Hu, G Lin Journal of Pharmaceutical and Biomedical Analysis 166, 6-12	2019
Toward the potential cure of leukemias in the next decade HM Kantarjian, MJ Keating, EJ Freireich Cancer 124 (22), 4301-4313	2018
MiR-144: a new possible therapeutic target and diagnostic/prognostic tool in cancers O Kooshkaki, Z Rezaei, M Rahmati, P Vahedi, A Derakhshani, O Brunetti, ... International journal of molecular sciences 21 (7), 2578	2020
Targeting nucleotide metabolism as the nexus of viral infections, cancer, and the immune response Y Ariav, JH Ch’ng, HR Christofk, N Ron-Harel, A Erez Science advances 7 (21), eabg6165	2021
Clinical pharmacokinetics and pharmacodynamics of dasatinib D Levêque, G Becker, K Bilger, S Natarajan-Amé Clinical Pharmacokinetics 59, 849-856	2020
Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options. MS DN, X Jiang, JM Brandwein, J Valencia-Serna, KC Remant, H Uludağ Drug Discovery Today 24 (7), 1355-1369	2019
Current perspectives for the treatment of chronic myeloid leukemia EA KARAKULAK, İC Haznedaroğlu Turkish Journal of Medical Sciences 49 (1), 1-10	2019
Applying antibodies inside cells: principles and recent advances in neurobiology, virology and oncology C Zhang, RM Ötjengerdes, J Roewe, R Mejias, ALJ Marschall BioDrugs 34, 435-462	2020

1 - 20

计算机程序会自动估算并确定日期和引用次数。